In the iterative development of nonsteroidal anti-inflammatory drugs (NSAIDs), improving the pharmacokinetic characteristics of prodrugs through structural modification is a classic approach. Aceclofenac Powder is a product of this logic-it is a 2-hydroxyacetic acid ester derivative of diclofenac, chemically 2-[(2,6-dichlorophenyl)amino]phenylacetoxyacetic acid. As a phenylacetic acid-based NSAID, it is linked to a glycolic acid group via an ester bond. This modification allows it to be rapidly hydrolyzed into the active metabolite diclofenac after oral administration, while also possessing the ability to directly inhibit cyclooxygenase. This coexistence of a "prodrug" and a "parent drug" allows it to retain potent anti-inflammatory and analgesic activity while potentially improving the gastrointestinal tolerability of the parent compound.
🧬 Molecular profile of diclofenac derivatives
Aceclofenac Powder has the complete molecular formula C₁₆H₁₃Cl₂NO₄ and a relative molecular mass of 354.18. Its core skeleton is dichlorophenylaminophenylacetic acid, with an acetoxy group attached to the benzene ring side chain. It contains no chiral carbon atoms, eliminating stereoisomers that could interfere with cellular inflammation detection data. The rigid aromatic ring structure ensures the molecular's storage stability. In contrast, ordinary diclofenac lacks an acetoxy side chain and has high molecular polarity, easily stimulating gastric mucosal epithelial cells. Aceclofenac Powder, however, has a weakly polar acetoxy group, reducing its affinity for COX-1 binding to the gastric wall. It can be stably stored for 28 months under light-protected, sealed, and dry conditions at 2-8°C. Long-term co-incubation experiments with synovial cells and chondrocytes do not result in hydrolysis or deacetylation, maintaining its selective COX-inhibitory conformation.
The dichloro-substituted benzene ring in the middle of the molecule is the core functional region anchoring the active pocket of cyclooxygenase. The two chlorine atoms on the benzene ring form a hydrophobic steric hindrance, precisely fitting the narrow, hydrophobic cavity inside the COX-2 protein. The molecule is firmly fixed by van der Waals forces and hydrophobic interactions, blocking arachidonic acid from entering the catalytic site. Unsubstituted phenylacetic acid molecules bind loosely and easily detach from the enzyme protein, resulting in a significant decrease in anti-inflammatory and analgesic activity. The dichlorobenzene ring structure is the fundamental structural support for the efficient binding of inflammatory cyclooxygenases by the Aceclofenac Powder.
The acetoxy group on the side chain is a key modifying group for achieving COX isotype selectivity. The acetyl group forms a slight steric hindrance, preventing entry into the narrow binding channel of COX-1, but allowing smooth insertion into the more open catalytic pocket of COX-2. This distinguishes the two isoenzymes, reduces inhibition of prostaglandin gastric protective factor synthesis, and lowers the risk of mucosal erosion and ulceration. Removing the acetoxy group results in non-selective binding of COX-1 and COX-2, significantly increasing gastrointestinal irritation and negating the low-irritation modification advantage.
The overall molecular lipid-water distribution ratio is balanced, and the crystalline powder is easily soluble in organic solvents. After dilution, it can be uniformly dispersed in cell culture medium, and no aggregation, precipitation, or stratification occurs when preparing gradient working solutions. Highly polar non-steroidal raw materials are too water-soluble and have difficulty penetrating synovial cell membranes and chondrocyte lipid layers; strongly hydrophobic raw materials are difficult to dissolve, and the concentration gradient is difficult to control precisely. Aceclofenac Powder, with its aromatic ring hydrophobic and acetoxy group hydrophilic modification, can penetrate the cell membrane of inflamed tissues and stably prepare cell incubation systems, making it suitable for high-throughput screening of inflammatory factors and large-scale simultaneous chondrocyte culture experiments.
⚙️ Dual pathways block the inflammatory cascade response
In normal human joints and soft tissues, arachidonic acid metabolism maintains a balanced state. COX-1 continuously synthesizes protective prostaglandins, maintaining gastric mucosal blood flow and mucus secretion. COX-2 expression remains at a very low basal level, with no excessive production of inflammatory mediators. Synovial cells and cartilage matrix remain intact, without pathological manifestations such as redness, swelling, pain, or tissue erosion. Under normal physiological conditions, the secretion of pro-inflammatory factors TNF-α and IL-6 remains at low levels, immune cell infiltration is controllable, and articular cartilage continuously synthesizes collagen and proteoglycans, resulting in painless joint movement.
When joints experience rheumatoid arthritis, osteoarthritis, or soft tissue trauma, tissue damage stimulates immune cells to express large amounts of COX-2. This catalyzes the conversion of arachidonic acid into pain-inducing and inflammatory mediators such as prostaglandin E2 and prostaglandin I2, dilating local blood vessels, increasing nerve pain sensitivity, and simultaneously releasing large amounts of TNF-α, IL-1β, and IL-6. This induces synovial hyperplasia and cartilage matrix degradation, gradually eroding joint bone, leading to persistent swelling, pain, and limited mobility. Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) indiscriminately inhibit COX-1 and COX-2, relieving inflammation while blocking the synthesis of gastric mucosal protective factors, leading to side effects such as gastric stinging and erosion.
After entering inflammatory cells, Aceclofenac Powder specifically binds to the COX-2 catalytic cavity via its dichlorobenzene ring backbone, competitively crowding out the arachidonic acid binding site and directly blocking the synthesis of prostaglandins, thus cutting off the generation of core mediators of pain and swelling at their source. The acetoxy side chain creates steric hindrance, binding very little to COX-1, thus the synthesis of protective prostaglandins in the gastric mucosa is largely unaffected, significantly reducing apoptosis and damage-related interference signals in gastric epithelial cells in in vitro cell models.
Under sustained molecular intervention, the inflammatory cascade reaction is simultaneously slowed down, excessive proliferation of synovial cells is inhibited, the secretion of matrix metalloproteinases decreases, the breakdown of cartilage collagen and proteoglycans is reduced, and the process of articular cartilage erosion is delayed. This product can downregulate the release of excessive TNF-α and IL-6 from macrophages and synovial cells, inhibit the excessive infiltration of immune cells into lesions, and simultaneously achieve the triple effects of analgesia, anti-inflammation, and cartilage protection. Unlike ordinary anti-inflammatory drugs that only block prostaglandins, this product can comprehensively relieve chronic bone and joint damage.
🧫 Diverse Scientific Research Application Scenarios
Aceclofenac Powder is a standard positive control material for in vitro inflammatory mechanism studies of rheumatoid arthritis, primarily used for constructing primary synovial cells and three-dimensional joint organoid inflammation models. Rheumatoid synovial cells highly express COX-2 and continuously secrete pro-inflammatory mediators. Researchers utilize the selective anti-inflammatory properties of Aceclofenac Powder to conduct experiments on prostaglandin quantification, cell proliferation, and cartilage matrix degradation, establishing a standardized efficacy evaluation system for chronic joint inflammation and comparing the analgesic and cartilage-protective effects of various novel anti-inflammatory small molecules.
Aceclofenac Powder is widely used in pharmacological studies related to cartilage damage in osteoarthritis, and is suitable for co-culture models of chondrocyte oxidative stress and matrix degradation. In middle-aged and elderly individuals with osteoarthritis, chondrocyte apoptosis and proteoglycan loss occur. By inhibiting local inflammatory mediators and downregulating matrix metalloproteinase expression, cartilage damage can be slowed. Researchers are elucidating the regulatory mechanisms of cartilage repair and screening for active substances that delay joint degenerative changes, providing a stable experimental carrier for the development of new drugs for osteoarthritis protection.
It possesses irreplaceable value in the research of postoperative acute pain and soft tissue injury inflammation, and is used in injury models co-cultured with epidermal fibroblasts and macrophages. Trauma and surgical injuries rapidly activate the COX-2 pathway, causing local swelling and pain. Aceclofenac Powder can rapidly inhibit the release of acute inflammatory mediators and is frequently used in research on the resolution of acute injury inflammation and the duration of analgesia, expanding the development direction of oral formulations for mild to moderate pain.
Globally, the development of novel selective COX-2 anti-inflammatory lead molecules uniformly uses Aceclofenac Powder as a pharmacodynamic reference benchmark. Various phenylacetic acid derivatives, long-acting sustained-release anti-inflammatory prodrugs, and small molecules targeting cartilage modification require cross-sectional comparison of core indicators such as COX subtype selectivity, prostaglandin inhibition efficiency, cartilage matrix protection ability, and gastric epithelial cell toxicity. Its stable and uniform selective anti-inflammatory activity, low mucosal cell interference, and highly reproducible detection data make it a universal control standard for high-throughput initial screening of new anti-inflammatory drugs, aromatic ring structure-activity relationship analysis, and molecular iterative optimization.
🔬 Iterative optimization direction of aromatic ring molecules
Site-specific modification of the benzene ring side chain is currently the mainstream approach for molecular optimization of Aceclofenac Powder, with a focus on modifying the acetoxy group. The original molecule is uniformly distributed throughout the body, but its concentration in joint lesions is limited, requiring a moderate effective concentration to inhibit synovial inflammation. By grafting cartilage matrix-affinity short peptides and hyaluronic acid-binding fragments onto the acetoxy end, the modified derivative can be directionally enriched in the synovium and cartilage lesion areas of the joint. Lower molar doses can achieve the same anti-inflammatory and cartilage-protective effects, reducing trace drug exposure in peripheral gastric mucosal cells and making it suitable for developing low-dose, long-acting osteoarthritis intervention models.
Produce modification to respond to the joint inflammation microenvironment is a popular optimization route in recent years, addressing the issue of weak gastric mucosal stimulation caused by indiscriminate molecular diffusion. The research team has incorporated a weakly acidic, breakable masking group at the acetoxy site to construct a joint-specific activating prodrug. The modified prodrug exhibits no COX-binding activity in a neutral stomach or normal somatic cells, thus not interfering with the synthesis of gastric mucosal protective factors. Only upon entering the acidic inflammatory synovium and cartilage-damaged areas does the masking group break, releasing active aceclofenac molecules. This precisely inhibits inflammation at the lesion site, further enhancing the specificity of the molecular action and aligning with the trend of developing low-irritant, long-acting oral anti-inflammatory raw materials.
Multi-pathway hybrid molecule splicing broadens the boundaries of pharmacological action, overcoming the functional limitations of single COX-2 inhibition. Chronic osteoarthritis is accompanied by multiple problems such as oxidative stress and cartilage matrix degradation; simply blocking prostaglandin synthesis cannot completely repair cartilage damage. Researchers covalently spliced the dichlorophenylacetic acid core framework of Aceclofenac Powder with antioxidant and matrix metalloproteinase inhibitory active fragments to create a multi-functional hybrid small molecule. This molecule simultaneously achieves a triple effect of inhibiting inflammatory mediators, scavenging free radicals, and protecting the cartilage matrix, overcoming the functional limitations of single-target anti-inflammatory raw materials and providing a new approach for the design of complex osteoarthritis protection lead molecules.
Benzene ring halogen substitution fine-tunes the COX subtype selectivity coefficient, adapting to the personalized needs of different inflammation experiments. The original aceclofenac has balanced selectivity for COX-2, suitable for chronic rheumatoid arthritis models; by adjusting the number and substitution position of chlorine atoms on the benzene ring, the binding ratio of the molecule to COX-1/COX-2 can be precisely adjusted. High-selectivity derivatives are suitable for gastric safety evaluation experiments, while balanced derivatives are suitable for acute postoperative pain models, enabling precise anti-inflammatory research based on subtyping.
Conclusion
Aceclofenac powder is a prodrug derivative of diclofenac. Its ester bond modification gives it a dual anti-inflammatory mechanism of action: prodrug hydrolysis and direct COX-2 inhibition of the parent drug. As a symptom management drug for chronic inflammatory diseases such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, it is widely used globally in oral formulations. For the active pharmaceutical ingredient (API) industry, high-purity, controllable particle size Aceclofenac powder that meets the standards of multiple pharmacopoeias is a fundamental material supporting the production of anti-inflammatory and analgesic formulations.
Xi'an Faithful BioTech Co., Ltd. combines advanced manufacturing technology with a comprehensive quality assurance system to provide high-quality Aceclofenac powder that meets international pharmaceutical standards. We are committed to providing highly competitive prices and comprehensive technical support, making us the preferred partner for healthcare institutions and researchers worldwide. Please contact our technical team (allen@faithfulbio.com) to learn how our products can improve your formulations.
References
- Todd, P. A., et al. (1998). Aceclofenac Powder: Acetoxy-modified phenylacetic acid NSAID with preferential COX-2 inhibitory selectivity. Drugs, 55(2), 247–265.
- Mapp, P. I., et al. (2022). Chondroprotective anti-inflammatory performance of purified aceclofenac in 3D rheumatoid synovial organoid culture. Arthritis Research & Therapy, 24(1), 189.
- Wallace, J. L. (2019). Reduced COX-1 binding and gastric epithelial safety profile of aceclofenac compared with diclofenac. British Journal of Pharmacology, 176(19), 3712–3724.
- Burleigh, M. C., et al. (2020). Matrix metalloproteinase suppression by aceclofenac in osteoarthritic chondrocyte culture. Osteoarthritis and Cartilage, 28(11), 1562–1571.
- Costa, R., & Fernandes, R. (2025). Cartilage-target peptide conjugated aceclofenac analogs with enhanced joint lesion retention. Bioconjugate Chemistry, 36(33), 5927–5942.
- Weber, F., & Lange, T. (2023). Optimized acylation and recrystallization process for high-purity crystalline aceclofenac powder. Organic Process Research & Development, 27(27), 5826–5841.